SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future
9 references·2 citing·45 second hop
Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future (2018)Pilot study assessing the direct medical …Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)Availability of evidence of b…A global comparison of the cost of patented cancer drugs in relation to global differences in wealth (2017)A global comparison of the co…Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment (2016)Target prices for mass produc…Pricing in the Market for Anticancer Drugs (2015)Pricing in the Market for Ant…Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries (2014)Evidence-informed frameworks …Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care (2014)Delivering maximum clinical b…Viewing the Kenyan health system through an equity lens: implications for universal coverage (2011)Viewing the Kenyan health sys…Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis (2008)Medicine prices, availability…Assessing the economic burden of breast cancer in a US managed care population (2007)Assessing the economic burden…Patients’ pathways to cancer care in Tanzania: documenting and addressing social inequalities in reaching a cancer diagnosis (2022)Patients’ pathways to cancer …Pricing of oral generic cancer medicines in 25 European countries; findings and implications (2019)Pricing of oral generic cance…Delivering affordable cancer care in high-income countries (2011)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology (2012)Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways (2016)Improving access to high‐cost cancer drugs in Latin America: Much to be done (2017)Cost-effectiveness thresholds: methods for setting and examples from around the world (2018)Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis (1995)Stage, Age, Comorbidity, and Direct Costs of Colon, Prostate, and Breast Cancer Care (1995)Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data (2002)The costs of breast cancer prior to and following diagnosis (2010)Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality (2011)INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES (2012)Mental Accounting and Consumer Choice (1985)Fairness as a Constraint on Profit Seeking: Entitlements in the Market (2000)Mental Accounting and Consumer Choice (2008)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Projections of Global Mortality and Burden of Disease from 2002 to 2030 (2006)World Development Report 2012: Gender equality and development (2012)Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes (2015)Essential medicines for cancer: WHO recommendations and national priorities (2016)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)A descriptive framework for country-level analysis of health care financing arrangements (2001)Equity and health sector reforms: can low-income countries escape the medical poverty trap? (2001)Household catastrophic health expenditure: a multicountry analysis (2003)Factors associated with incomplete or delayed vaccination across countries: A systematic review (2016)Examining levels, distribution and correlates of health insurance coverage in Kenya (2017)Socio-economic inequality and inequity in use of health care services in Kenya: evidence from the fourth Kenya household health expenditure and utilization survey (2019)Driving a decade of change: HIV/AIDS, patents and access to medicines for all (2011)Access to cancer medications in low- and middle-income countries (2013)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Evidence-based public policy making for medicines across countries: findings and implications for the future (2021)Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis (2013)A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Pricing of pharmaceuticals is becoming a major challenge for health systems (2020)Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature (2021)Barriers in access to oncology drugs — a global crisis (2022)Using Numbers in Qualitative Research (2010)THE WORLD MEDICINES SITUATION 2011 (2011)The Economic Costs of Type 2 Diabetes: A Global Systematic Review (2015)Essential medicines for universal health coverage (2016)Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval (2019)Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis (2019)
this work references cited by second hop

References

  • 2008Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis926 cited
  • 2017Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13600 cited
  • 2015Pricing in the Market for Anticancer Drugs452 cited
  • 2014Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries163 cited
  • 2017A global comparison of the cost of patented cancer drugs in relation to global differences in wealth152 cited
  • 2011Viewing the Kenyan health system through an equity lens: implications for universal coverage143 cited
  • 2007Assessing the economic burden of breast cancer in a US managed care population94 cited
  • 2014Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care86 cited
  • 2016Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment69 cited

Cited by

  • 2022Patients’ pathways to cancer care in Tanzania: documenting and addressing social inequalities in reaching a cancer diagnosis53 cited
  • 2019Pricing of oral generic cancer medicines in 25 European countries; findings and implications48 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work